Kunal Dhiman
YOU?
Author Swipe
View article: Glutaric acid associates with early detection of cognitive impairment deciphering the association with depression
Glutaric acid associates with early detection of cognitive impairment deciphering the association with depression Open
Background The initiation of cognitive impairment is triggered by a myriad of pathological events occurring decades before clinical symptoms manifest. Perturbed glucose and fatty acid metabolism notably contribute to the development of cog…
View article: Exploring the protective potential of bilobalide against amyloid beta peptide 1‐42‐induced toxicity in BE(2)‐M17 cells: insights via cell viability and cellular energetics
Exploring the protective potential of bilobalide against amyloid beta peptide 1‐42‐induced toxicity in BE(2)‐M17 cells: insights via cell viability and cellular energetics Open
Background Reliable treatment approaches for addressing early cognitive impairment and Alzheimer’s disease (AD) are currently lacking. Given the multifactorial nature of AD, therapeutic strategies need to focus on disease‐specific biochemi…
View article: Development of a blood‐based biomarker signature for detection of cognitive impairment through a targeted metabolomics approach deciphering the association with depression
Development of a blood‐based biomarker signature for detection of cognitive impairment through a targeted metabolomics approach deciphering the association with depression Open
Background A series of pathological episodes set off the development of cognitive impairment, which precede years before the onset of clinical symptoms. Disrupted glucose and fatty acid metabolism notably contributes to the development of …
View article: Evaluating the therapeutic efficacy of phytochemicals in ameliorating cytotoxic effects of amyloid beta
Evaluating the therapeutic efficacy of phytochemicals in ameliorating cytotoxic effects of amyloid beta Open
Background There is lack of reliable treatment approaches to combat early cognitive impairment, as well as Alzheimer’s disease (AD). Since AD is a multifactorial disease, therapeutic approaches must be targeted on disease specific multiple…
View article: Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study
Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study Open
Background: Biomarkers that are indicative of early biochemical aberrations are needed to predict the risk of dementia onset and progression in Alzheimer’s disease (AD). We assessed the utility of cerebrospinal fluid (CSF) neurofilament li…
View article: Neuroserpin, a crucial regulator for axogenesis, synaptic modelling and cell–cell interactions in the pathophysiology of neurological disease
Neuroserpin, a crucial regulator for axogenesis, synaptic modelling and cell–cell interactions in the pathophysiology of neurological disease Open
View article: Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals
Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals Open
Introduction Fatty acid–binding protein 3 (FABP3) is a biomarker of neuronal membrane disruption, associated with lipid dyshomeostasis—a notable Alzheimer's disease (AD) pathophysiological change. We assessed the association of cerebrospin…
View article: Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer’s Disease
Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer’s Disease Open
Alzheimer's disease (AD) is the leading cause of dementia that has remained a major medical, sociocultural and economical challenge globally. Previously developed treatments like anticholinesterase inhibitors (AChEIs) and N-methyl-D-aspart…
View article: Cerebrospinal fluid fatty acid binding protein 3: A screening biomarker for preclinical Alzheimer’s disease
Cerebrospinal fluid fatty acid binding protein 3: A screening biomarker for preclinical Alzheimer’s disease Open
Background Preclinical Alzheimer’s disease (AD) is a silent, asymptomatic stage of AD, classified into three sub‐stages based on amyloid positivity, neuronal injury and presence of subtle cognitive decline. Pathophysiological biomarkers ar…
View article: Elevated levels of synaptic protein GAP‐43 associate with brain tauopathy, atrophy and cognition in Alzheimer’s disease
Elevated levels of synaptic protein GAP‐43 associate with brain tauopathy, atrophy and cognition in Alzheimer’s disease Open
Background Synaptic dysfunction is an early pathophysiological event, which associates with cognitive aberrations in Alzheimer’s disease (AD). Growth associated protein 43 (GAP‐43) is a nervous tissue specific protein, which plays a crucia…
View article: Neurofilament light chain in psychiatric and neurodegenerative disorders: A ‘c‐reactive protein’ for the brain?
Neurofilament light chain in psychiatric and neurodegenerative disorders: A ‘c‐reactive protein’ for the brain? Open
Background Accurate diagnosis of a neurodegenerative disorder, in particular distinguishing primary psychiatric from neurological disorders, can be challenging. There is a need for biomarkers to reduce the diagnostic odyssey and improve ou…
View article: Elevated levels of synaptic protein GAP‐43 associate with brain tauopathy, atrophy and cognition in Alzheimer’s disease
Elevated levels of synaptic protein GAP‐43 associate with brain tauopathy, atrophy and cognition in Alzheimer’s disease Open
Elevated levels of synaptic protein GAP‐43 associate with brain tauopathy, atrophy and cognition in Alzheimer’s disease
View article: Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease
Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease Open
Introduction: This study assessed the utility of cerebrospinal fluid (CSF) neurofilament light (NfL) in Alzheimer's disease (AD) diagnosis, its association with amyloid and tau pathology, as well as its potential to predict brain atrophy, …
View article: Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis
Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis Open